Literature DB >> 32129130

Two-stage optimal designs based on exact variance for a single-arm trial with survival endpoints.

Guogen Shan1.   

Abstract

Sample size calculation based on normal approximations is often associated with the loss of statistical power for a single-arm trial with a time-to-event endpoint. Recently, Wu (2015) derived the exact variance for the one-sample log-rank test under the alternative and showed that a single-arm one-stage study based on exact variance often has power above the nominal level while the type I error rate is controlled. We extend this approach to a single-arm two-stage design by using exact variances of the one-sample log-rank test for the first stage and the two stages combined. The empirical power of the proposed two-stage optimal designs is often not guaranteed under a two-stage design setting, which could be due to the asymptotic bi-variate normal distribution used to estimate the joint distribution of the test statistics. We adjust the nominal power level in the design search to guarantee the simulated power of the identified optimal design being above the nominal level. The sample size and the study time savings of the proposed two-stage designs are substantial as compared to the one-stage design.

Entities:  

Keywords:  Cancer trials; exact variance; one-sample log-rank test; optimal designs; two-stage designs

Year:  2020        PMID: 32129130      PMCID: PMC7415526          DOI: 10.1080/10543406.2020.1730869

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  15 in total

Review 1.  Comparing survival of a sample to that of a standard population.

Authors:  Dianne M Finkelstein; Alona Muzikansky; David A Schoenfeld
Journal:  J Natl Cancer Inst       Date:  2003-10-01       Impact factor: 13.506

2.  Randomized two-stage Phase II clinical trial designs based on Barnard's exact test.

Authors:  Guogen Shan; Changxing Ma; Alan D Hutson; Gregory E Wilding
Journal:  J Biopharm Stat       Date:  2013       Impact factor: 1.051

3.  Letter to the Editor: A novel confidence interval for a single proportion in the presence of clustered binary outcome data (SMMR, 2019).

Authors:  Hua Zhang; Guogen Shan
Journal:  Stat Methods Med Res       Date:  2019-04-04       Impact factor: 3.021

4.  Exact Unconditional Tests for Dichotomous Data When Comparing Multiple Treatments With a Single Control.

Authors:  Guogen Shan; Carolee Dodge-Francis; Gregory E Wilding
Journal:  Ther Innov Regul Sci       Date:  2020-01-06       Impact factor: 1.778

5.  Phase II cancer clinical trials with a one-sample log-rank test and its corrections based on the Edgeworth expansion.

Authors:  Xiaoqun Sun; Paul Peng; Dongsheng Tu
Journal:  Contemp Clin Trials       Date:  2010-10-01       Impact factor: 2.226

6.  Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.

Authors:  David R Spigel; Thomas J Ervin; Rodryg A Ramlau; Davey B Daniel; Jerome H Goldschmidt; George R Blumenschein; Maciej J Krzakowski; Gilles Robinet; Benoit Godbert; Fabrice Barlesi; Ramaswamy Govindan; Taral Patel; Sergey V Orlov; Michael S Wertheim; Wei Yu; Jiping Zha; Robert L Yauch; Premal H Patel; See-Chun Phan; Amy C Peterson
Journal:  J Clin Oncol       Date:  2013-10-07       Impact factor: 44.544

7.  Minimax and admissible adaptive two-stage designs in phase II clinical trials.

Authors:  Guogen Shan; Hua Zhang; Tao Jiang
Journal:  BMC Med Res Methodol       Date:  2016-08-02       Impact factor: 4.615

8.  Two-stage optimal designs with survival endpoint when the follow-up time is restricted.

Authors:  Guogen Shan; Hua Zhang
Journal:  BMC Med Res Methodol       Date:  2019-04-03       Impact factor: 4.615

9.  One-stage and two-stage designs for phase II clinical trials with survival endpoints.

Authors:  John Whitehead
Journal:  Stat Med       Date:  2014-05-12       Impact factor: 2.373

10.  Design of Phase II cancer trials evaluating survival probabilities.

Authors:  L Douglas Case; Timothy M Morgan
Journal:  BMC Med Res Methodol       Date:  2003-04-03       Impact factor: 4.615

View more
  4 in total

1.  Partial correlation coefficient for a study with repeated measurements.

Authors:  Guogen Shan; Ece Bayram; Jessica Z K Caldwell; Justin B Miller; Jay J Shen; Shawn Gerstenberger
Journal:  Stat Biopharm Res       Date:  2020-07-20       Impact factor: 1.452

2.  Randomized two-stage optimal design for interval-censored data.

Authors:  Guogen Shan
Journal:  J Biopharm Stat       Date:  2021-12-10       Impact factor: 1.503

3.  Bayesian single-arm phase II trial designs with time-to-event endpoints.

Authors:  Jianrong Wu; Haitao Pan; Chia-Wei Hsu
Journal:  Pharm Stat       Date:  2021-06-04       Impact factor: 1.234

4.  Optimal two-stage designs based on restricted mean survival time for a single-arm study.

Authors:  Guogen Shan
Journal:  Contemp Clin Trials Commun       Date:  2021-01-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.